Alatiris Inc. Competitors

Empatica is a full-stack digital health company and an MIT spin-off, with offices in Boston (MA), Milan (Italy), and Seoul (South Korea). We specialize in the development, production, and deployment of medical-grade wearables and digital biomarkers, powered by an AI-driven platform designed for continuous health monitoring and the early detection of medical conditions. The FDA-cleared Empatica Health Monitoring Platform consists of the medical-grade EmbracePlus and EmbraceMini wearables and the world’s largest selection of validated digital measures, enabling thousands of institutional partners to remotely collect patient health data, in trials and studies on sleep, stress, epilepsy, and more. Empatica’s Embrace wearable was the world’s first FDA-cleared smartwatch in neurology to detect epileptic seizures. In 2024, we launched its successor, EpiMonitor, with all of the most loved features of Embrace and even more. EpiMonitor is an all-in-one wearable and smartphone application solution for detecting possible generalized tonic-clonic seizures, alerting caregivers during emergencies, and monitoring epilepsy. It is the only FDA-cleared wrist-worn wearable and app combination for epilepsy monitoring in the US.

Pear Therapeutics, Inc., which is traded on Nasdaq as PEAR, is the parent company of Pear Therapeutics (US), Inc. Pear is the leader in developing and commercializing software-based medicines, called prescription digital therapeutics (PDTs). Pear aims to redefine care through the widespread use of clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Pear has the first end-to-end platform to discover, develop, and deliver PDTs to patients and a pipeline of products and product candidates across therapeutic areas, including the first three PDTs with disease treatment claims from the FDA. Pear’s product, reSET®, for the treatment of substance use disorder, was the first PDT to receive marketing authorization from the FDA to treat disease. Pear’s second product, reSET-O®, for the treatment of opioid use disorder, was the first PDT to receive Breakthrough Designation. Pear’s third product, Somryst® for the treatment of chronic insomnia, was the first PDT submitted through FDA’s traditional 510(k) pathway while simultaneously reviewed through FDA’s Software Precertification Pilot Program. For more information, visit Pear at www.peartherapeutics.com.

Welcome to Akili! At Akili, we believe there is potential for medicine to be developed, delivered and experienced in a completely different way. We’re bringing together world-class neuroscience with exceptional creativity and video game development to challenge the status quo of medicine. Our digital medicine is not delivered through a pill, but rather through a patented and captivating video game experience. Effective medicine that’s captivating and enjoyable to use – now that’s refreshing! We're continuously evaluating new technologies and are advancing a broad pipeline of programs to treat cognitive deficiency and improve symptoms associated with medical conditions across neurology and psychiatry, including attention-deficit hyperactivity/ disorder (ADHD), major depressive disorder (MDD), autism spectrum disorder (ASD) and various inflammatory diseases. And we're always looking for game-changers to join our team – to help us change the status quo of medicine and ignite new hope for those living with cognitive deficits. Imagine what medicine can be®